Surrogate markers are just that, not the real thing.

The aim of using surrogate markers is to predict the future, and we all know how difficult that can be.

Generally one considers testing these "biomarkers" because there is a known plausible mechanism whereby the thing we are measuring might lead to the outcome of interest.

A very common example is measuring blood pressure. Originally people who had "malignant hypertension" were found to have 50% mortality in 1 year. Many trials later we know that a rise in blood pressure of even 20/10 systolic/diastolic is associated with increased cardiovascular mortality.

"Associated with" does not mean caused, as the two things might both be results of yet another factor operating on them both.

Cholesterol is another common surrogate for this same clinical outcome of cardiovascular disease and mortality. The evidence that elevated cholesterol causes cvs disease is from a weak association. Nearly all the trial evidence is from use of statin drugs, and these have multiple relevant "pleiotropic" effects, quite apart from any possible benefit of cholesterol lowering.

Lowering cholesterol probably has very little to do with their benefits. It is a surrogate marker still, but only because of it leading to statin medication. The non statin drug ezetimibe lowers cholesterol with only a very "modest" proven benefit on clinical outcomes (2% over 7 years.)

Biomarkers ideally should be causally related to +/- clinical outcomes, more QALYs

That doesn't mean they have to be causally related to one "disease." Diseases as medically defined are artificial abstractions, just a small part of overall ill health in an individual.

Many factors over many years, are usually needed to produce one "disease." These same factors may contribute along the way to development of various other apparently unrelated "diseases."

Maximizing QALYs is the clinical outcome it is all about - compressing morbidity into a shorter time at the end of life.

State and trait biomarkers.

I'm looking forward to people using The Ruggiero-Klinghardt (RK) Protocol in diseases such as schizophrenia associated with inflammation and as yet with no cause found.
"Thus, inflammatory cytokines in the peripheral blood were suggested to be either state or trait biomarkers. State biomarkers refer to specific cytokines elevated in schizophrenia and normalized with antipsychotics. Trait biomarkers are cytokines that are elevated in schizophrenia and are not normalized following antipsychotic treatment (43).

The first to consider is our beliefs, attitudes (and hence habits.)

To quote briefly from Dr. John Harrison's book "Love Your Disease. It's Keeping You Healthy"...

"Disease is both self-created and self-cured. ...Having established the ways in which we contribute to the developement of our diseases, we will go on to investigate the ways in which we can minimise our discomfort and, if we so desire, eliminate our disease entirely. The decision is ours.
The delightful thing about such a concept is that you, the patient, can once again assume control over both your disease and your destiny...
...healing ourselves can be great fun - not only fun, but an opportunity to reorganise our whole lives, learn about ourselves and our environment, understand our children and , perhaps more importantly, prevent disease in both ourselves and our offspring."

Valuable surrogate markers in common use

These are proxy indicators of susceptibility to later disease.

Footsteps per day, as measured by a pedometer.

Natural walking speed.

Hours of sleep, especially before midnight.

Tiny amounts of albumin protein in one's urine in the morning (microalbuminuria.)

Blood pressure (ideally by 24 hour monitor)

Homocysteine in blood (ideally 4 hours after 4gm of methionine orally.)

Transferrin saturation and serum ferritin.

Not so valuable ones which probably shouldn't be in common use

Total cholesterol - TC/HDL ratio is better. In a 2013 article on reversal of cardiology practices comes the quote...
"What are the take homes lessons of the last decade when it comes to lipid management? First, the trials discussed above argue that lipid targets cannot be considered reliable surrogate endpoints. The medical literature is rich with examples of studies that used surrogate endpoints leading us to adopt ultimately harmful drugs (23). Future studies of statins should be powered to examine important clinical endpoints, and whether novel biomarkers will be able to overcome these deficits remains to be seen."

PSA - evidence is that there's little benefit from screening healthy males for prostate cancer.

DEXA scan measurement of bone mineral density - a very weak predictor of fracture risk. Roger Zebaze at Melbourne University is developing a better test of bone density.

Weakness, drug use and diseases increasing falls risk are much better predictors of fracture.

From surrogate markers page back to main index page of site.

Need help or have a helpful tip to share, or an experience others can learn from?

You can have your own page on this site, be anonymous if you prefer, and help other people or get useful opinions.

It's very quick and easy

eg, from 110/70 to 130/80.


Is there something else you would like to read about?
This search button will bring up anywhere on this site your words are mentioned...


Custom Search


The contactpage.

If you are interested in a home study course on examination of the spine, please send me your e-mail address by the contact form.